Maykin Ho - 14 Sep 2023 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Director
Signature
/s/ Joshua Pinto, as Attorney-in-Fact for Maykin Ho
Issuer symbol
NMRA
Transactions as of
14 Sep 2023
Net transactions value
$0
Form type
4
Filing time
18 Sep 2023, 17:50:21 UTC
Previous filing
23 Jun 2023
Next filing
23 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Award $0 +27,802 $0.000000 27,802 14 Sep 2023 Common Stock 27,802 $17.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to the option shall vest and become exercisable on the date of the 2024 Annual Meeting, subject to the Reporting Person continuing in service on the Board through such vesting date.